- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: GSK-3196165 | GSK3196165 | MOR-103 | MOR103
Compound class: Antibody
Comment: Otilimab (MOR103, GSK3196165) is a clinical stage fully human IgG1λ antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2). It is being investigated as a therapeutic for inflammatory diseases. MOR103 was developed using MorphoSys' HuCAL® technology, and has been fully out-licensed otilimab to GSK. MOR103 is claimed as MOR-04357 in patent WO2006122797A2 (by BLAST peptide sequence matching) .
|No information available.|
|Summary of Clinical Use|
|Otilimab was advanced into clinical trials, initially in rheumatoid arthritis and multiple sclerosis .
SARS-CoV-2 and COVID-19: Otilimab was investigated in a Phase 2 RCT, in patients with severe COVID-19, as a mechanism to reduce severe inflammatory lung complications, improve lung function and potentially improve clinical outcomes. However, in October 2021, GSK announced that this trial had failed to detect efficacy, and that development of otilimab for COVID-19 was being discontinued.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01023256||Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis||Phase 1/Phase 2 Interventional||MorphoSys AG||1|
|NCT01517282||Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis||Phase 1/Phase 2 Interventional||MorphoSys AG||2|
|NCT03970837||Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)||Phase 3 Interventional||GlaxoSmithKline||2|
|NCT04333147||Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)||Phase 3 Interventional||GlaxoSmithKline|
|NCT02683785||A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis||Phase 2 Interventional||GlaxoSmithKline|
|NCT04376684||Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease||Phase 2 Interventional||GlaxoSmithKline|